Witteveen, H.J.

patient b-blocker mortality surgery cardioselective heart disease cardioselective b-blockers heart failure study 30- day mortality intensi fied dose failure cardioselective b-blocking agents therapy 30- intensi effect noncardiac surgery fev 1 b-blocker therapy trial 30- day b-blocker use analysis beta-blocker fi ndings agent relationship smoking status association bene ficial infarction metoprolol bisoprolol group respir ratio ficial follow-up smoking netherland function bax jj subject boersma e center perioperative baseline medication history intervention salpeter noncardiac 5 odds ratio intensi fied dosage status copd severity groups hypertension outcome cardioselective beta-blockers value low-dose lung health study table cardioselective b-blockade fev 1/fvc thomson ir american bblocker b-blocking nding result copd 5 angiotensin-converting enzyme inhibitors body mass index artery department diabetes mellitus fidence interval